Ziopharm Oncology
NASDAQ: TCRTBoston, US · Delaware corporation · 1 known investors
Biotech
Founders & leadership
KL
Kevin LafondExecutive Officer
WF
Wyche FowlerDirector
MB
Murray BrennanDirector
RK
Randal KirkDirector
CB
Caesar BelbelExecutive Officer
TM
Timothy McInerneyDirector
JC
James CannonDirector
MW
Michael WeiserDirector
JL
Jonathan LewisExecutive Officer, Director
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$19.5MraisedSep 2019 · 1 investors · BiotechnologyRule 506(b)
▶$19.5MraisedSep 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sath ShuklaExecutive Officer
- Heidi HagenDirector
- Scott BraunsteinDirector
- Elan Z. EzicksonDirector
- Douglas W. PaganDirector
- Scott TarriffDirector
- Eleanor De GrootExecutive Officer
- Robert HadfieldExecutive Officer
- David M. MauneyExecutive Officer
- Kevin G. LafondExecutive Officer
- Laurence J.N. CooperExecutive Officer, Director
- Jill BuckExecutive Officer
- Offering amount
- $19.5M
- Amount sold
- $19.5M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$105.1MraisedAug 2019 · 5 investors · BiotechnologyRule 506(b)
▶$105.1MraisedAug 2019 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Laurence J.N. CooperExecutive Officer, Director
- Kevin G. LafondExecutive Officer
- Robert HadfieldExecutive Officer
- David M. MauneyExecutive Officer
- Jill BuckExecutive Officer
- Scott TarriffDirector
- Sath ShuklaExecutive Officer
- Heidi HagenDirector
- Scott BraunsteinDirector
- Elan Z. EzicksonDirector
- Douglas W. PaganDirector
- Eleanor De GrootExecutive Officer
- Offering amount
- $105.1M
- Amount sold
- $105.1M
- Sales commissions
- $1M
- Placement agents
- Raymond James & Associates, Inc.
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50MraisedNov 2018 · 7 investors · BiotechnologyRule 506(b)
▶$50MraisedNov 2018 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Douglas W. PaganDirector
- Robert HadfieldExecutive Officer
- Kevin G. LafondExecutive Officer
- Scott TarriffDirector
- Scott BraunsteinDirector
- David MauneyExecutive Officer
- Laurence J.N. CooperExecutive Officer, Director
- James A. CannonDirector
- Elan Z. EzicksonDirector
- Offering amount
- $107M
- Amount sold
- $50M
- Sales commissions
- $2.5M
- Placement agents
- Raymond James & Associates, Inc.
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$120MraisedJul 2016 · 1 investors · BiotechnologyRule 506(b)
▶$120MraisedJul 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Laurence J.N. CooperExecutive Officer
- Scott TarriffDirector
- Kevin G. LafondExecutive Officer
- Wyche Fowler, Jr.Director
- Caesar BelbelExecutive Officer
- Michael WeiserDirector
- Randal J. KirkDirector
- James CannonDirector
- Francois LebelExecutive Officer
- Murray BrennanDirector
- Offering amount
- $120M
- Amount sold
- $120M
- First sale
- Jun 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$57.5MraisedJan 2015 · 1 investors · BiotechnologyRule 506(b)
▶$57.5MraisedJan 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kevin LafondExecutive Officer
- Wyche FowlerDirector
- Murray BrennanDirector
- Randal KirkDirector
- Caesar BelbelExecutive Officer
- Timothy McInerneyDirector
- James CannonDirector
- Michael WeiserDirector
- Jonathan LewisExecutive Officer, Director
- Offering amount
- $57.5M
- Amount sold
- $57.5M
- First sale
- Jan 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.